Every week, there is chatter of new routes to funding drug development that ultimately bring medicines to patients more quickly. On Friday, a group of billionaires offered up the latest route, unveiling the capital they’ve put behind a new biomedical research institute with broad ambitions across technologies and disease areas.
Arena BioWorks said Friday it’s “inspired by the success of Bell Labs” and will lead new research initiatives and create for-profit biotech companies “seamlessly under one roof.” It promises a quicker translational research model, has the backing of big names, and plans to put scientists in the driver’s seat and a footprint in the industry’s beating heart of Kendall Square in Cambridge, MA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.